Tempest Therapeutics adjourns special meeting again; needs 75% vote for governance change

Tempest Therapeutics, Inc.

Special meeting reconvened Aug 17, 2026, adjourned again due to insufficient votes for proposal.
Quorum present: 10,601,849 shares (71.6% of 14,806,997 outstanding as of May 28, 2026 record date).
Proposal: replace supermajority voting requirements and permit stockholder action by written consent; requires 75% affirmative vote.
Meeting reconvenes Sept 15, 2026 at 12:00 p.m. ET via webcast; record date unchanged.
Proxies previously submitted will be voted unless revoked; no changes to proposal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.